ArticleEye (London, England)2026
Intraocular foreign bodies in Asia: insights from the Global Burden of Disease 2019 Study.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntraocular foreign bodies (IOFBs) constitute a significant public health concern that hinders the accumulation of human capital in countries in Asia. This research aims to identify and project the time trend of the IOFB disease burden in Asia to 2035.
methodsWe utilised data collected from the Global Health Data Exchange (GHDx) query tool. Time Trends of disability-adjusted life years (DALYs) and incidence of IOFBs were calculated. Age- and gender-specific disease burden of IOFBs in 2019 was also analysed. A Bayesian age-period cohort (BAPC) model with integrated nested Laplace approximations (INLA) was applied to project the number and rate of the disease burden attributable to IOFB from 2020 to 2035.
resultsIn Asia, the DALYs number increased from 290,521.62 (95% UI: 146,816.5-513,604.1) in 1990 to 388,363.39 (95% UI: 206,296.3-668,164.9) in 2019. The number of DALYs showed an upward trend until the age of 45-49 years, and then decreased in later age groups. The age-standardised incidence rate (ASIR) of China is projected to increase substantially from 719.03 in 2019 to 3127.06 in 2035. Singapore is projected to experience a slight decline, while the remaining six countries are projected to have slight, steady increases in ASIR.
conclusionCountries in Asia are facing a huge disease burden of IOFB, and ASIRs are projected to increase over the next 15 years in most Asian countries. These findings contribute valuable evidence-based guidance for public health policy in disease prevention, medical planning and resource allocation pertaining to IOFBs in Asia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.